Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome. 1980

R S Stern, and I M Marks, and D Mawson, and D K Luscombe

Forty obsessive-compulsive ritualizers received nightly placebo or clomipramine up to 225 mgs nocte for 8 months, and received behavioural treatment (exposure to vivo) from weeks 4 to 10. Plasma concentrations of clomipramine and its primary metabolite N-desmethylclomipramine steadily increased over the first 4 weeks of treatment after which they remained relatively steady. Plasma levels correlated significantly with dose and with outcome but not with side effects. Patients with plasma clomipramine levels in the range 100-250 ng/ml and N-desmethylclomipramine levels between 230-550 ng/ml were found to improve significantly more than patients outside these ranges, thus suggesting a therapeutic window for clomipramine and its primary metabolite.

UI MeSH Term Description Entries
D009771 Obsessive-Compulsive Disorder An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension. Anankastic Personality,Neurosis, Obsessive-Compulsive,Anankastic Personalities,Disorder, Obsessive-Compulsive,Disorders, Obsessive-Compulsive,Neuroses, Obsessive-Compulsive,Neurosis, Obsessive Compulsive,Obsessive Compulsive Disorder,Obsessive-Compulsive Disorders,Obsessive-Compulsive Neuroses,Obsessive-Compulsive Neurosis,Personalities, Anankastic,Personality, Anankastic
D002997 Clomipramine A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. Chlorimipramine,Anafranil,Chlomipramine,Clomipramine Hydrochloride,Clomipramine Maleate (1:1),Clomipramine Monohydrochloride,Hydiphen,Hydrochloride, Clomipramine,Monohydrochloride, Clomipramine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

R S Stern, and I M Marks, and D Mawson, and D K Luscombe
April 1988, The British journal of psychiatry : the journal of mental science,
R S Stern, and I M Marks, and D Mawson, and D K Luscombe
January 1982, The British journal of psychiatry : the journal of mental science,
R S Stern, and I M Marks, and D Mawson, and D K Luscombe
August 1990, Journal of clinical psychopharmacology,
R S Stern, and I M Marks, and D Mawson, and D K Luscombe
January 1979, Communications in psychopharmacology,
R S Stern, and I M Marks, and D Mawson, and D K Luscombe
January 2012, International clinical psychopharmacology,
R S Stern, and I M Marks, and D Mawson, and D K Luscombe
November 1992, Journal of the American Academy of Child and Adolescent Psychiatry,
R S Stern, and I M Marks, and D Mawson, and D K Luscombe
August 1996, Journal of clinical psychopharmacology,
R S Stern, and I M Marks, and D Mawson, and D K Luscombe
January 2004, Depression and anxiety,
R S Stern, and I M Marks, and D Mawson, and D K Luscombe
January 1977, The Journal of international medical research,
Copied contents to your clipboard!